CHICAGO, Dec. 14 Sword Diagnostics, Inc. is pleased to announce that the United States Patent Office (USPTO) has issued patent number 7,599,057 titled "Method and Apparatus for Detection of Biological Organisms using Raman Scattering" to the company. The patent covers the core technology which focuses on improved sensitivity.
Advertisement
"The issuance of this patent supports the underlying strategy as we move forward with our continued development and commercialization," said Dave Dingott, CEO and President of Sword Diagnostics. "The feedback from our immunoassay customers validates the high degree of need in the market for a technology that delivers improved sensitivity without compromising in cost or complexity of the test."
Advertisement
About Sword Diagnostics
Sword Diagnostic's mission is to improve existing medical diagnostic tests by providing additional sensitivity to each currently available antibody-based test as well as allowing clinicians to monitor new markers that are not detectable with current technology. This will allow earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer's disease. Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.
The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry. The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.
www.sworddiagnostics.com
SOURCE Sword Diagnostics, Inc.
